Hepatitis B Before and After Hepatocellular Carcinoma
| Autor: | Murat Harputluoglu, Brian I. Carr |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Hepatitis B virus medicine.medical_specialty Hepatitis B vaccine business.industry Incidence (epidemiology) Gastroenterology virus diseases Entecavir Hepatitis B medicine.disease medicine.disease_cause Tenofovir alafenamide digestive system diseases Hepatocellular carcinoma Internal medicine medicine business neoplasms Viral load medicine.drug |
| Zdroj: | Journal of Gastrointestinal Cancer. 52:1206-1210 |
| ISSN: | 1941-6636 1941-6628 |
| DOI: | 10.1007/s12029-021-00745-4 |
| Popis: | Hepatitis B virus (HBV) is the one of most common causes of the hepatocellular carcinoma (HCC), especially in eastern world. The aim of this review is to try to understand the relationship between HBV and HCC and to reveal the role of prevention and treatment of HBV infection in reducing the incidence of HCC. Strategies to prevent HCC due to HBV can be classified into three categories. These are primary, secondary, and tertiary preventions. Hepatitis B vaccine is now in the most vital position in preventing HBV-associated HCC. In patients with chronic hepatitis B infection, suppressing viral load with potent antivirals such as tenofovir disoproxil fumarate (TDF) and entecavir (ETV) prevents the development of HCC and improves prognosis by reducing recurrence after HCC treatments. There is currently no clear consensus on which of these drugs should be preferred. Although data on tenofovir alafenamide (TAF) are scarce, available data with TDF suggest that TAF therapy will also be a strong actor for HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink